Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype

The problem of fibrosing interstitial lung diseases (ILDs) unites specialists from different areas: pulmonologists, radiologists, therapists, rheumatologists, occupational doctors and others. Actual achievements in studying fibrosing ILDs which are connected with development of immunology and molecular biological methods for the determination of biomarkers, new principles of image-diagnostics of lung pathology, search of new therapeutic “targets”, dictate the necessity of integration of knowledge by specialists from different areas of medicine for improvement pharmacotherapy algorithms. These algorithms directed to decrease fibrosis progression in ILDs, improve quality and increase lifespan of the patients.

1. Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. 2020;383(10):958-968. DOI: 10.1056/NEJMra2005230

2. Wong AW, Ryerson CJ, Guler SA. Progression of fibrosing interstitial lung disease. Respir Res. 2020;21(1):32. DOI: 10.1186/s12931-020-1296-3

3. George PM, Spagnolo P, Kreuter M, et al.; Erice ILD working group. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. 2020;8(9):925-934. DOI: 10.1016/S2213-2600(20)30355-6

4. Vancheri C, Basile A. Multidisciplinary approach to interstitial lung diseases: Nothing is better than all of us together. Diagnostics (Basel). 2020;10(7):488. DOI: 10.3390/diagnostics10070488

5. Furini F, Carnevale A, Casoni GL, et al. The role of the multidisciplinary evaluation of interstitial lung diseases: systematic literature review of the current evidence and future perspectives. Front Med (Lausanne). 2019;6:246. DOI: 10.3389/fmed.2019.00246

6. Elicker BM, Kallianos KG, Henry TS. The role of high-resolution computed tomography in the follow-up of diffuse lung disease. Eur Resp Rev. 2017;26(144):170008. DOI: 10.1183/16000617.0008-2017

7. Walsh SLF, Devaraj A, Enghelmayer JI, et al. Role of imaging in progressive-fibrosing interstitial lung diseases. Eur Resp Revc. 2018;27(150):180073. DOI: 10.1183/16000617.0073-2018

8. Chanda D, Otoupalova E, Smith SR, et al. Developmental pathways in the pathogenesis of lung fibrosis. Mol Aspects Med. 2019;65:56-69. DOI: 10.1016/j.mam.2018.08.004

9. Wijsenbeek M, Kreuter M, Olson A, et al. Progressive fibrosing interstitial lung diseases: Current practice in diagnosis and management. Curr Med Res Opin. 2019;35(11):2015-2024. DOI: 10.1080/03007995.2019.1647040

10. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: Incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2(7):566-572. DOI: 10.1016/S2213-2600(14)

11. Kolb M, Vas;ikov;i M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20(1):57. DOI: 10.1186/s12931-019-1022-1

12. Nasonov EL, Aleksandrova EN, Novikov AA. Autoimmune rheumatic diseases - problems of immunopathology and personalized treatment. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk = Annals of the Russian Academy of Medical Sciences. 2015;(2):169-182 (In Russ.)]. DOI: 10.15690/vramn.v70i2.1310

13. Goldblatt F, O'Neill SG. Clinical aspects of autoimmune rheumatic diseases. Lancet. 2013;382(9894):797-808. DOI: 10.1016/S0140-6736(13)61499-3

14. Atzeni F, Gerardi MC, Barilaro G, et al. Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. Expert Rev Clin Immunol. 2018;14(1):69-82. DOI: 10.1080/1744666X.2018.1411190

15. Fischer A, Distler J. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clin Rheumatol. 2019;38(10):2673-2681. DOI: 10.1007/s10067-019-04720-0

16. Sambataro D, Sambataro G, Pignataro F, et al. Patients with interstitial lung disease secondary to autoimmune diseases: How to recognize them? Diagnostics (Basel). 2020;10(4):208. DOI: 10.3390/diagnostics10040208

17. Perelas A, Silver RM, Arrossi AV, et al. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8(3):304-320. DOI: 10.1016/S2213-2600(19)30480-1

18. Barba T, Mainbourg S, Nasser M, et al. Lung diseases in inflammatory myopathies. Semin Respir Crit Care Med. 2019;40(2):255-270. DOI: 10.1055/s-0039-1685187

19. Hervier B, Uzunhan Y. Inflammatory myopathy-related interstitial lung disease: From pathophysiology to treatment. Front Med (Lausanne). 2020;6:326. DOI: 10.3389/fmed.2019.00326

20. Betteridge Z, Tansley S, Shaddick G, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019;101:48-55. DOI: 10.1016/j.jaut.2019.04.001

21. Long K, Danoff SK. Interstitial lung disease in polymyositis and dermatomyositis. Clin Chest Med. 2019;40(3):561-572. DOI: 10.1016/j.ccm.2019.05.004

22. Gonzdlez-Moreno J, Raya-Cruz M, Losada-Lopez I, et al. Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: A case report and literature review. Rheumatol Int. 2018;38(7):1293-1296. DOI: 10.1007/s00296-018-3991-7

23. Ciang NC, Pereira N, Isenberg DA. Mixed connective tissue disease - enigma variations? Rheumatology (Oxford). 2017;56(3):326-333. DOI: 10.1093/rheumatology/kew265

24. Perelas A, Arrossi AV, Highland KB. Pulmonary manifestations of systemic sclerosis and mixed connective tissue disease. Clin Chest Med. 2019;40(3):501-518. DOI: 10.1016/j.ccm.2019.05.001

25. Spagnolo P, Lee JS, Sverzellati N, et al. The lung in rheumatoid arthritis: Focus on interstitial lung disease. Arthritis Rheumatol. 2018;70(10):1544-1554. DOI: 10.1002/art.40574

26. Bendstrup E, M0ller J, Kronborg-White S, et al. Interstitial lung disease in rheumatoid arthritis remains a challenge for clinicians. J Clin Med. 2019;8(12):2038. DOI: 10.3390/jcm8122038

27. Wu EK, Ambrosini RD, Kottmann RM, et al. Reinterpreting evidence of rheumatoid arthritis-associated interstitial lung disease to understand etiology. Curr Rheumatol Rev. 2019;15(4):277-289. DOI: 10.2174/1573397115666190116102451

28. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Respir Med. 2020;8(8):807-815. DOI: 10.1016/S2213-2600(20)30225-3

29. Spagnolo P, Balestro E, Aliberti S, et al. Pulmonary fibrosis secondary to COVID-19: A call to arms? Lancet Respir Med. 2020;8(8):750-752. DOI: 10.1016/S2213-2600(20)30222-8

30. Mira-Avendano I, Abril A, Burger CD, et al. Interstitial lung disease and other pulmonary manifestations in connective tissue diseases. Mayo Clin Proc. 2019;94:309-325. DOI: 10.1016/j.mayocp.2018.09.002

31. Akulkina LA, Brovko MYu, Sholomova VI, et al. Interstitial pneumonia with autoimmune features (IPAF): multidisciplinary diagnosis in pulmonology and rheumatology. Klinicheskaya farmakologiya I terapiya = Clinical Pharmacology and Therapy Journal. 2018;18(27):5-10 (In Russ.).

32. Graney BA, Fischer A. Interstitial pneumonia with autoimmune features. Ann Am Thorac Soc. 2019;16(5):525-533. DOI: 10.1513/AnnalsATS.201808-565CME

33. Wilfong EM, Lentz RJ, Guttentag A, et al. Interstitial pneumonia with autoimmune features: An emerging challenge at the intersection of rheumatology and pulmonology. Arthritis Rheumatol. 2018;70(12):1901-1913. DOI: 10.1002/art.40679

34. Adegunsoye A, Oldham JM, Bellam SK, et al. Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases. Ann Am Thorac Soc. 2019;16(5):580-588. DOI: 10.1513/AnnalsATS.201807-443OC

35. Wollin L, Distler JHW, Redente EF, et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019;54(3):1900161. DOI: 10.1183/13993003.001612019

36. Landi C, Bergantini L, Cameli P, et al. Idiopathic pulmonary fibrosis serum proteomic analysis before and after nintedanib therapy. Sci Rep. 2020;10:9378. DOI: 10.1038/s41598-020-66296-z

37. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-2082. Erratum in: N Engl J Med. 2015;373(8):782. DOI: 10.1056/NEJMoa1402584

38. Crestani B, Huggins JT, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: Results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019;7(1):60-68. DOI: 10.1016/S2213-2600(18)30339-4

39. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518-2528. DOI: 10.1056/NEJMoa1903076

40. Seibold JR, Maher TM, Highland KB, et al. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: Data from the SENSCIS trial. Ann Rheum Dis. 2020;79(11):1478-1484. DOI: 10.1136/annrheumdis-2020-217331

41. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718-1727. DOI: 10.1056/NEJMoa1908681

42. Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8(5):453-460. DOI: 10.1016/S2213-2600(20)30036-9

43. Avdeev SN, Ananyeva LP, Zhilyaev EV, et al. The resolution of the Expert Council on Interstitial Lung Diseases in Systemic Scleroderma (Moscow, October 14, 2019). Modern Rheumatology Journal. 2020;14(1):125-128 (In Russ.). DOI: 10.14412/1996-7012-2020-1-125-128.

44. Sinha A, Patel AS, Siegert RJ, et al. The King's Brief Interstitial Lung Disease (KBILD) questionnaire: An updated minimal clinically important difference. BMJ Open Respir Res. 2019;6(1):e000363. DOI: 10.1136/bmjresp-2018-000363

45. Liu R, Lei C, Liao X, et al. Semi-quantitative analysis for the dynamic chest CT imaging features from onset to recovery in severe and critical COVID-19. Radiol Infect Dis. 2020;7(3):114-122. DOI: 10.1016/j.jrid.2020.07.003